HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) markedly improve the survival benefits of advanced melanoma and non-small cell lung cancer (NSCLC). Nevertheless, only a subset of patients could benefit from such a therapy. Novel and effective clinical biomarkers are needed to assess ICI treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenjing, Lin, Zhijuan, Shi, Fuyan, Wang, Qiang, Kong, Yujia, Ren, Yanfeng, Lyu, Juncheng, Sheng, Chao, Li, Yuting, Qin, Hao, Wang, Suzhen, Wang, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315784/
https://www.ncbi.nlm.nih.gov/pubmed/35884556
http://dx.doi.org/10.3390/cancers14143495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315784/
https://www.ncbi.nlm.nih.gov/pubmed/35884556
http://dx.doi.org/10.3390/cancers14143495

Ejemplares similares